Heidelberg Pharma AG annual gross profit
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Heidelberg Pharma AG Gross Profit Growth & History (HPHA)
Heidelberg Pharma AG's gross profit was €1.2M for fiscal 2025.
View full Heidelberg Pharma AG company overviewHeidelberg Pharma AG annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-11-30 | €1.2M | −€3.9M | −76.53% |
| 2024 | 2024-11-30 | €5.1M | −€1.5M | −23.30% |
| 2023 | 2023-11-30 | €6.6M | −€7.2M | −52.21% |
| 2022 | 2022-11-30 | €13.8M | €16.8M | — |
| 2021 | 2021-11-30 | −€3.0M | −€5.8M | — |
| 2020 | 2020-11-30 | €2.9M | −€680,000 | −19.05% |
| 2019 | 2019-11-30 | €3.6M | €2.1M | +144.52% |
| 2018 | 2018-11-30 | €1.5M | €520,000 | +55.32% |
| 2017 | 2017-11-30 | €940,000 | €390,000 | +70.91% |
| 2016 | 2016-11-30 | €550,000 | −€590,000 | −51.75% |
| 2015 | 2015-11-30 | €1.1M | −€1.1M | −49.11% |
| 2014 | 2014-11-30 | €2.2M | −€7.4M | −76.76% |
| 2013 | 2013-11-30 | €9.6M | €240,000 | +2.55% |
| 2012 | 2012-11-30 | €9.4M | €3.7M | +64.62% |
| 2011 | 2011-11-30 | €5.7M | €5.7M | — |
| 2010 | 2010-11-30 | €0 | — | — |
Heidelberg Pharma AG gross profit trends
Over the last five fiscal years, Heidelberg Pharma AG's gross profit decreased from €2.9M to €1.2M, a change of −€1.7M.
About the metric
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
Calculation and source
reported and calculated gross profit
TickerStat uses gross profit reported in company official filings when available. Otherwise, it calculates gross profit as reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Heidelberg Pharma AG source filings ↗Community posts
Heidelberg Pharma reports early myeloma responses and selects a development dose
Heidelberg Pharma ($HPHA) presented Phase 1 results for pamlectabart tismanitin, its experimental antibody-drug conjugate for relapsed or refractory multiple myeloma. Among 31 evaluable patients in dose cohorts five through nine, 13 respond ...
